Is TRVI a Buy? What to Consider in 2026
Short answer
The bull case for Trevi Therapeutics (TRVI) rests on Haduvio Phase 3 in IPF-related chronic cough: The lead program advanced into Phase 3 in early 2026 after positive Phase 2b CORAL data and overall alignment with the FDA at an End-of-Phase 2 meeting. Product revenue (TTM) is ~$0 (clinical stage, no approved products). If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value. Whether TRVI is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing a single lead candidate, Haduvio (oral nalbuphine extended release), for chronic cough. Haduvio is designed to act on the cough reflex both centrally and peripherally as a kappa-opioid agonist and mu-opioid antagonist (a KAMA mechanism), a different approach from the P2X3 antagonists that most rivals pursue. Trevi is targeting three indications: chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in non-IPF interstitial lung disease (ILD), and refractory chronic cough (RCC). The company has no marketed products and generates no product revenue, so it funds itself through equity raises and operates at a net loss, which is typical for a company at this stage. The investment picture is a classic high-risk, high-reward clinical biotech. Trevi has reported positive mid-stage data: its Phase 2b CORAL trial in IPF-related chronic cough (N=165) met its primary endpoint across all dose groups in June 2025, and its Phase 2a RIVER trial in RCC showed a statistically significant reduction in cough frequency in March 2025. After an End-of-Phase 2 meeting with the FDA, Trevi initiated its first Phase 3 trial in IPF-related chronic cough and a Phase 2b trial in RCC in early 2026. An April 2026 stock offering raised roughly $162 million in net proceeds, extending the projected cash runway into 2030. The upside case is a first-in-class chronic cough drug in indications with no approved therapies; the downside case is that a late-stage trial fails or the FDA declines approval, which would remove most of the value underpinning the stock.
What's the case for buying TRVI?
1. Haduvio Phase 3 in IPF-related chronic cough.
The lead program advanced into Phase 3 in early 2026 after positive Phase 2b CORAL data and overall alignment with the FDA at an End-of-Phase 2 meeting. IPF-related chronic cough has no approved therapy, so a successful Phase 3 followed by approval would give Trevi a first-in-class product. This readout is the single most important catalyst for the stock.
2. Refractory chronic cough expansion.
Trevi is also running a Phase 2b trial of Haduvio in refractory chronic cough (RCC), a far larger patient population, after its Phase 2a RIVER trial met its primary endpoint in 2025. RCC is a market that has frustrated larger competitors, and success here would materially widen Haduvio's commercial opportunity beyond the smaller IPF indication.
3. Differentiated mechanism.
Haduvio's kappa-agonist, mu-antagonist (KAMA) mechanism is distinct from the P2X3 antagonists that dominate rival chronic cough pipelines. Management highlights that Haduvio has shown statistically significant cough reductions across both IPF and RCC patients, a breadth its P2X3 peers have not consistently matched, which is the core of the differentiation thesis.
4. Funded runway into 2030.
An April 2026 offering added roughly $162 million in net proceeds on top of about $171.8 million in cash at the end of Q1 2026, giving a projected runway into 2030. That funding is meant to carry the company through its planned IPF and RCC trials and potential FDA approval without an imminent need to raise more capital, reducing near-term dilution pressure.
What are the risks to TRVI?
Trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value. Even with a large cash balance, the company burns cash every quarter and will likely need additional financing before Haduvio could reach the market, and equity raises dilute existing shareholders (the April 2026 offering issued 11.6 million new shares). Because Haduvio is derived from an opioid (nalbuphine), it faces scheduling, safety, and tolerability scrutiny that non-opioid rivals avoid. It also competes with well-capitalized programs from Merck, GSK, Bayer, and others. Finally, the ~$2 billion market value already embeds significant expectations of clinical and regulatory success, so disappointing data could trigger a sharp decline.
How is TRVI valued? (as of MAY 2026)
Snapshot for TRVI as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Market cap: ~$2.0 billion
- Share price: ~$13.87
- Cash and marketable securities (Q1 2026): ~$171.8 million
- April 2026 offering net proceeds: ~$162 million
- Product revenue (TTM): ~$0 (clinical stage, no approved products)
- Projected cash runway: into ~2030
As a clinical-stage biotech, Trevi has no product revenue and runs at a net loss, so traditional valuation multiples like price-to-earnings do not apply. The roughly $2 billion market capitalization reflects investor expectations for Haduvio's clinical trials rather than current financial performance. The April 2026 capital raise and the resulting projected runway into 2030 are meant to fund the company through its key Phase 3 and Phase 2b readouts.
How do you decide if TRVI is a buy?
Rather than asking whether TRVI is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold TRVI indirectly through an index or sector ETF before adding more.
For the full picture, see the TRVI stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about TRVI against your real portfolio and see your actual exposure before deciding.
The bottom line on TRVI
The bottom line: Trevi Therapeutics's story right now is Haduvio Phase 3 in IPF-related chronic cough, with product revenue (ttm) at ~$0 (clinical stage, no approved products). If you believe that narrative continues, the call is about sizing TRVI sensibly and checking overlap with what you own; if you doubt it (the risk: trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around TRVI with Walnut
Use Trevi Therapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is TRVI a good stock to buy right now?
+
The case for Trevi Therapeutics right now is Haduvio Phase 3 in IPF-related chronic cough, with product revenue (ttm) at ~$0 (clinical stage, no approved products). If you believe that thesis holds, TRVI is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Trevi Therapeutics do?
+
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing a single lead candidate, Haduvio (oral nalbuphine extended release), for chronic cough.
What are the main risks of TRVI?
+
Trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value. Even with a large cash balance, the company burns cash every quarter and will likely need additional financing before Haduvio could reach the market, and equity raises dilute existing shareholders (the April 2026 offering issued 11.6 million new shares). Because Haduvio is derived from an opioid (nalbuphine), it faces scheduling, safety, and tolerability scrutiny that non-opioid rivals avoid. It also competes with well-capitalized programs from Merck, GSK, Bayer, and others. Finally, the ~$2 billion market value already embeds significant expectations of clinical and regulatory success, so disappointing data could trigger a sharp decline.
What does Trevi Therapeutics do?
+
Trevi is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine extended release), an experimental therapy for chronic cough in idiopathic pulmonary fibrosis, other interstitial lung disease, and refractory chronic cough. It has no approved products yet.
Does TRVI make any money?
+
No. Trevi has no approved products and generates no product revenue. Like most clinical-stage biotechs, it operates at a net loss and funds its research through cash raised in stock offerings, most recently about $162 million in net proceeds in April 2026.
What is Haduvio?
+
Haduvio is Trevi's lead drug candidate, an oral extended-release formulation of nalbuphine. It works on the cough reflex as a kappa-opioid agonist and mu-opioid antagonist (a KAMA mechanism), a different approach from the P2X3 antagonists used by many competing chronic cough programs.
How has Haduvio performed in clinical trials?
+
Trevi reported positive results in its Phase 2b CORAL trial in IPF-related chronic cough (N=165), which met its primary endpoint across all dose groups in June 2025, and in its Phase 2a RIVER trial in refractory chronic cough, which met its primary endpoint in March 2025. Phase 3 testing began in 2026.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell TRVI; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.